1	Astrocyte-mediated disruption of ROS homeostasis in Fragile X mouse model
2	
3	Gregory G. Vandenberg <sup>1</sup> , Neal J. Dawson <sup>2</sup> , Alison Head <sup>1</sup> , Graham R. Scott <sup>2</sup> , and
4	Angela L. Scott <sup>1</sup>
5	
6	<sup>1</sup> Department of Pathology and Molecular Medicine, McMaster University, 1200 Main St.
7	West, Hamilton, Ontario L8N 3Z5, Canada; <sup>2</sup> Department of Biology, McMaster University,
8	1280 Main St. West, Hamilton, Ontario L8S 4K1, Canada
9	
10	Running title: Astrocyte-mediated ROS dysregulation in FXS
11	
12	Keywords: Fragile X Syndrome, astrocyte, mouse model, oxidative stress, mitochondrial
13	respiration, reactive species, antioxidants
14	
15	Number of words: Abstract: 217 words; Introduction: 847 words; Discussion: 1814 words
16	Number of figures: 5 (no color print required)
17	
18	Address correspondence to:
19	Dr. Angela Scott
20	Department of Pathology and Molecular Medicine, McMaster University, 1200 Main St.
21	West, Hamilton, Ontario L8N 3Z5, Canada
22	Tel: 905-525-9140, x20531
23	Email: <scottan@mcmaster.ca></scottan@mcmaster.ca>

24	Acknowledgements: We sincerely thank Colin Nurse for his support and expert advice
25	on this project. G. Scott, and A. Scott are funded by Natural Sciences and Engineering
26	Research Council operating grants. The authors declare no competing financial interests.
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	

## 41 Abstract

Astrocytes, glial cells within the brain, work to protect neurons during high levels 42 of activity by maintaining oxidative homeostasis via regulation of energy supply and 43 antioxidant systems. In recent years, mitochondrial dysfunction has been highlighted as 44 an underlying factor of pathology in many neurological disorders. In animal studies of 45 Fragile X Syndrome (FXS), the leading genetic cause of autism, higher levels of 46 reactive oxygen species, lipid peroxidation, and protein oxidation within the brain 47 48 indicates that mitochondria function is also altered in FXS. Despite their integral contribution to redox homeostasis within the CNS, the role of astrocytes on the 49 occurrence or progression of neurodevelopmental disorders in this way is rarely 50 51 considered. This study specifically examines changes to astrocyte mitochondrial function and antioxidant expression that may occur in FXS. Using the *Fmr1* knockout 52 (KO) mouse model, mitochondrial respiration and reactive oxygen species (ROS) 53 54 emission were analyzed in primary cortical astrocytes. While mitochondrial respiration was similar between genotypes, ROS emission was significantly elevated in *Fmr1* KO 55 astrocytes. Notably, NADPH-oxidase 2 expression in *Fmr*1 KO astrocytes was also 56 enhanced but only changes in catalase antioxidant enzyme expression were noted. 57 Characterization of astrocyte factors involved in redox imbalance is invaluable to 58 uncovering potential sources of oxidative stress in neurodevelopmental disorders and 59 more specifically, the intercellular mechanisms that contribute to dysfunction in FXS. 60 61

62

# 64 Introduction

During development, oxidative homeostasis is highly regulated within the 65 nervous system and a tight balance of free radicals is important for many developmental 66 processes (reviewed in Salim, 2017). However, deviations of either the production or 67 elimination of free radicals can result in oxidative stress associated with abnormal 68 increases to reactive oxygen species (ROS) that lead to DNA damage, protein loss and 69 lipid peroxidation (Cobley, Fiorello, & Bailey, 2018). Not surprisingly, several 70 71 neurodevelopmental disorders have been linked to oxidative stress, including autism spectrum disorders (ASDs); with the degree of oxidative stress directly correlated to the 72 severity of symptoms in some cases (Pangrazzi, Balasco, & Bozzi, 2020). In an animal 73 74 model of Fragile X Syndrome (FXS), a genetic disorder highly comorbid with anxiety, hyperactivity and ASDs, higher levels of ROS have been measured in various brain 75 tissues (el Bekay, et al., 2007; D'Antoni, et al., 2019). The pathology that underlies 76 77 abnormalities in redox regulation in neurodevelopmental disorders like FXS remain unclear, but several reports have linked it to mitochondrial dysfunction within the CNS. 78 FXS is the most common inherited cause of intellectual disability and ASD that is 79 caused by the instability of a CGG-repeated tract at the 5' end of the *Fmr*1 transcript, 80 which leads to hypermethylation and silencing of FMRP (Fragile X mental retardation 81 protein). FMRP functions as a translational regulator for several hundred downstream 82 proteins and is associated with synaptic polyribosomes and RNA granules in neurons 83 (Khayachi et al., 2018; Raspa, Wheeler, & Riley, 2017). In a recent study, impairment to 84 85 mitochondrial fusion behaviour led to developmental deficits in newly formed FXS hippocampal neurons (Shen et al., 2019). They found that FMRP deficiency resulted in 86

a decrease in Hungtinin mRNA and protein levels within hippocampal neurons that led 87 to a decrease in mitochondrial fusion gene expression, impaired mitochondrial fusion, 88 and reduced dendritic complexity and maturation. While this work demonstrated 89 mitochondrial dysfunction and the vulnerability of developing neurons in FXS, how this 90 mutation affects other neural cell types that also rely on FMRP during brain 91 92 development has not been studied. In the CNS, astrocytes play a significant role in regulating oxidative homeostasis, with the ability to either exacerbate oxidative stress 93 via the production of ROS or modulate resistance via the secretion of antioxidants (Jou, 94 95 2008; Blanc et al., 1998). Astrocytes normally express FMRP throughout development and a lack of FMRP has led to various impairments to astrocyte function, including 96 changes to glutamate uptake and catabolism (Higashimori, et al., 2016). One primary 97 goal of this study was to examine the consequence of FMRP deletion on mitochondrial 98 function and ROS emission in astrocytes in order to further elucidate their potential 99 100 contribution to oxidative stress in FXS.

During periods of oxidative stress, the supply of astrocyte-mediated antioxidants 101 is especially important for the protection of neurons susceptible to oxidative damage. 102 103 One particularly key role of astrocytes is the synthesis and exportation of glutathione to neurons (Wilson, 1997). Glutathione (GSH) acts to detoxify ROS within the brain and 104 105 deficiency of this tripeptide has been associated with mitochondrial damage and 106 neurodegeneration (Jain et al., 1991; Bains & Shaw, 1997). Astrocytes not only produce 107 high levels of GSH within the CNS but also supply neurons with the essential precursors 108 for GSH synthesis (Dringen et al., 1999). Furthermore, in response to high or low levels 109 of ROS, astrocytes can induce the expression of superoxide dismutase (SOD) or

nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, respectively (Wang et 110 al, 2018A). SOD is responsible for the dismutation of superoxide within the cytoplasm 111 and mitochondria, converting superoxide (O<sub>2</sub>-) produced from oxidative phosphorylation 112 into oxygen  $(O_2)$  and hydrogen peroxide  $(H_2O_2)$ , a less damaging form of ROS 113 degraded by other enzymes (reviewed in Wang et al, 2018B). The expression of SOD in 114 115 astrocytes appears particularly important to neuronal survival. In neuron-astrocyte cocultures, approximately half of the neurons die when cultured with SOD-deficient 116 astrocytes as compared with wild-types, and the surviving neurons show dramatic 117 decreases of synaptic proteins in the presence of glutamate (Kunze et al., 2013). Given 118 that excess glutamate has been associated with aberrant activity within the FXS brain, 119 changes to SOD expression in astrocytes could act to exacerbate glutamate-mediated 120 neuronal effects (Mahmoud et al, 2019). 121

In contrast to SOD, NADPH oxidase in astrocytes produces intracellular ROS 122 123 needed for redox signalling. Notably, overproduction of ROS via NADPH oxidase has been noted in hyperactive circuits, and greater activation of NADPH oxidase in the Fmr1 124 KO mouse brain has been previously reported (Wang et al, 2018A; el Bekay et al., 125 126 2007). Taken together, dysregulation of astrocyte-mediated antioxidant function in FXS may largely contribute to redox imbalance within the CNS and underscore many 127 128 downstream consequences to neuronal circuitry. In light of this, our study examined 129 several key enzymes involved in oxidative homeostasis within wild-type and *Fmr1* KO 130 astrocytes in order to promote our understanding of glial-mediated pathophysiology in FXS. 131

132

# **Materials and Methods**

134 *Ethical Approval.* Wildtype (WT) mice and *Fmr1* KO mice (background

135 FVB.129P2[B6]-Fmr1tm1Cgr) were housed and bred in the McMaster University Central

136 Animal Facility. All animal-handling procedures and experiments followed the guidelines

137 set by the Canadian Council on Animal Care and were approved by the McMaster

138 Animal Research Ethics Board (Animal Utilization Protocol 17-04-11).

139

Cortical Astrocyte Cell Culture. Each primary astrocyte culture was prepared from the 140 combination of brain tissue dissected from 3-4 WT or *Fmr1* KO pups at P1-P3. The 141 cortices were isolated from each brain and mechanically homogenized with a scalpel 142 143 blade. The cortices were then combined and chemically homogenized in 2.5% Trypsin (Invitrogen Canada Inc., Burlington, ON, Canada) in the presence of DNase I (Roche, 144 145 Penzburg, Upper Bavaria, Germany). After thorough trituration and passage through a 146 cell strainer (70 µm; Thermo Fisher Scientific, Waltham, Massachusetts, United States), the cell suspension was centrifuged for 5 minutes at 1400 rpm. The supernatant was 147 removed, and the pellet was resuspended in 20 mL of minimum essential media (MEM; 148 Invitrogen) supplemented with 6% glucose and 10% horse serum (Invitrogen). The cell 149 suspension was then placed in a T75 tissue culture flask and incubated at 37°C with 5% 150 CO<sub>2</sub> approximately 12-14 days. Media changes of half volume glia media (10 mL; 151 minimum essential media supplemented with 6% glucose and 10% horse serum) 152 occurred 24 hours after plating and then every two to three days. 153 At 80-90% cell confluence, the media was replaced with 0.05% trypsin-EDTA 154 and glial media and incubated for 5 minutes at 37° C. Following incubation, 5 mL of glial 155

media was added to the flask and the solution was repeatedly pipetted along the bottom of the flask to lift cells. All of the liquid suspension was removed and centrifuged at 200 rpm for 5 minutes. Each resulting pellet of cells was then used as one biological sample (n) and prepared for either respirometry measurements or protein assays as described below. Notably, no two replicates within any experiment were collected from cultured cells isolated from pups of the same litter. The sample number (n) is indicated for each experiment within the results section, as well as the individual figure legends.

The cells used for real-time respiration studies were resuspended in 1 mL of 163 respiration buffer (in mM: 0.5 EGTA, 3 MgCl<sub>2</sub>, 60 potassium lactobionate, 20 taurine, 10 164 KH<sub>2</sub>PO<sub>4</sub>, 20 Hepes, 110 sucrose, 1 g I–1 fatty acid-free bovine serum albumin; pH 7.1). 165 After thorough trituration, the cells were counted via a haemocytometer and a Zeiss 166 Axioimager M2 (x10) and were then immediately used for high resolution respirometry. 167 The cells collected for protein assays were resuspended in 1 mL of glial media. 168 The cell suspension was then centrifuged again at 1400 rpm for 5 minutes. The 169 supernatant was removed, and the pellet was flash-frozen in liquid nitrogen prior to 170 storage at -80° C. 171

172

Mouse Genotyping. At the time of tissue collection, tail segments (0.5-1 cm in length)
were also collected from the mice used for cell culture. A random selection of samples
from each group were used to confirm the genotypes of the mice using PCR as
previously described in Wallingford et al., (2017). Briefly, DNA extraction was completed
using the Extract-N-Amp<sup>TM</sup> PCR Kit according to the manufacturer's instructions
(catalog# XNAT2, Sigma-Aldrich). Prior to the PCR, the following primers were added to

each sample (with final primer concentrations of approximately 1 µM): CAC GAG ACT 179 AGT GAG ACG TG (mutant forward; primer oIMR2060; Jackson Laboratory, Bar 180 Harbor, ME, USA), TGT GAT AGA ATA TGC AGC ATG TGA (WT forward; primer 181 olMR6734; Jackson Laboratory), CTT CTG GCA CCT CCA GCT T (common; primer 182 oIMR6735; Jackson Laboratory). PCR reaction conditions were equivalent to those 183 outlined by Jackson Laboratory genotyping protocols for B6.129-Fmr1tm1Rbd/J 184 (http://jaxmice.jax.org/protocolsdb/f?p=116:2:::NO:2:P2 MASTER PROTOCOL ID,P 185 2 JRS CODE:4718,010504). Following PCR, the amplified DNA samples were run 186 through a 2% agarose gel. Gels were imaged using SYBR Safe DNA Gel Stain 187 188 (Invitrogen) and a ChemiDoc Imaging System (Bio-Rad) (data not shown). 189

*Mitochondrial Respiration and ROS Emission.* Respiration and ROS emission of 1 x 190 10<sup>6</sup> primary cortical astrocytes were measured simultaneously using high-resolution 191 respirometry (Oxygraph-2K, Oroboros Instruments, Innsbruck, Austria) in 2 mL of 192 respiration buffer (in mM: 0.5 EGTA, 3 MgCl<sub>2</sub>, 60 potassium lactobionate, 20 taurine, 10 193 KH<sub>2</sub>PO<sub>4</sub>, 20 Hepes, 110 sucrose, 1 g l-1 fatty acid-free bovine serum albumin; pH 7.1) 194 195 at 37°C. Respiration was measured from the rate of decline of O<sub>2</sub> concentration, while ROS emission was measured by the fluorescent detection of resorufin (excitation 196 wavelength of 525 nm and AmR filter set, Oroboros Instruments). For simultaneous 197 ROS detection, exogenous superoxide dismutase (22.5 U/mL), Ampliflu Red (15 µM) 198 and horseradish peroxidase (3 U/mL; which catalyses the generation of resorufin from 199 hydrogen peroxide and Ampliflu Red), was added to the respiration buffer. Exogenous 200  $H_2O_2$  solutions were used to calibrate the resorufin signal, such that ROS emission rate 201

was measured as the molar rate of  $H_2O_2$  appearance. After calibration, the 1 x 10<sup>6</sup> cells were added to a respirometry chamber and cells were permeabilized with the addition of digitonin (6  $\mu$ M; Djafarzadeh and Jakob, 2017) to the respirometry chamber.

After a 5-minute acclimation, LEAK respiration was stimulated with the addition of 205 10 mM glutamate (Sigma-Aldrich, St. Louis, MO, USA) and 1 mM malate (Sigma-206 207 Aldrich) to the respirometry chamber and readings were recorded for approximately 2 minutes following every treatment. Multiple complexes of the electron transport system 208 (during OXPHOS respiration in the presence of 10 mM glutamate and 1 mM malate) 209 210 were stimulated via progressive additions of 5 mM ADP and 5 mM pyruvate (complex I; Sigma-Aldrich), 10 mM of succinate (complexes I + II; Sigma-Aldrich), and 2 mM of 211 ascorbate and 0.5 mM of TMPD (complex IV; Sigma-Aldrich). After each addition of 212 substrate, respiration rates and H<sub>2</sub>O<sub>2</sub> emission rates were monitored and recorded until 213 a stable steady state was reached (approximately 2 minutes). Each experiment lasted 214 215 approximately 25 mins from time of the addition of Digitonin to the final respiration state 216 measurement.

217

*Microscopy.* Primary cultured astrocytes labelled with Mitotracker Red CMXRos
(Invitrogen) were imaged at 40x objective magnification using the Axio Observer Z1
inverted microscope, Axiocam 506 camera, and Zen Blue (2.0) Software (Zeiss;
Oberkochen, Germany). Cells were plated onto coverslips precoated with Poly-D-Lysine
(1 mg/mL; Sigma-Aldrich) and laminin (0.1 mg/mL; Invitrogen) at a density of 8000 cells
per coverslip. Cells were maintained in minimum essential media with 6% glucose
(Sigma-Aldrich) and 10% horse serum (Invitrogen) on coverslips for 7 days at 37°C.

Forty-five minutes prior to imaging, media was removed and the cells were incubated
with 25 nM Mitotracker Red CMXRos (Invitrogen) in phosphate buffered saline (Gibco;
Gaithersburg, MD, US). The dye solution was then removed and replaced by 1X PBS.
Cells were then imaged immediately (40x, Axio Observer Z1) within an onstage
incubation chamber maintained at 5% CO<sub>2</sub> and 37°C.

230

**Enzyme Activity.** Citrate synthase and cytochrome c oxidase activities were measured 231 using a protocol adapted from Dawson et al. (2016). Previously prepared samples (cell 232 culture pellets) were homogenized in 10 volumes of ice-cold homogenizing buffer A 233 [100 mmol I<sup>-1</sup> KH<sub>2</sub>PO<sub>4</sub> buffer, pH 7.2, containing 0.1% triton x-100, 1 mmol I<sup>-1</sup> EGTA, 1 234 mmol I<sup>-1</sup> EDTA and 1 mmol I<sup>-1</sup> phenylmethylsulfonyl fluoride (PMSF)]. Homogenates 235 were then centrifuged at 1000 g at 4°C and the supernatant was collected for use in 236 enzyme assays. The maximal activity for each sample was assayed at 37°C and 237 238 measured in triplicate.

Enzyme activity was determined as the difference between the rate measured 239 using all assay components and the background reaction rate. In the case of 240 241 cytochrome c oxidase, the background reaction rate is the oxidation rate of cytochrome c (oxidized) and for citrate synthase it is the reaction rate without oxaloacetate. 242 Measurements were carried out in 100 mmol I<sup>-1</sup> KH<sub>2</sub>PO<sub>4</sub> (pH 7.2) under the following 243 244 assay conditions: 0.2 mmol I<sup>-1</sup> reduced cytochrome c (Calzyme Laboratories) (molar extinction coefficient ( $\epsilon$ )=28.5 (mmol I<sup>-1</sup>)<sup>-1</sup> cm<sup>-1</sup> at 550 nm) for cytochrome c oxidase 245 [complex IV of the electron transport system (CIV)]; and 0.5 mmol I<sup>-1</sup> oxaloacetate, 0.15 246 247 mmol I<sup>-1</sup> acetyl-coA, 0.15 mmol I<sup>-1</sup> 5,5'- dithiobis-2-nitrobenzoic acid (ε=14.15 (mmol I<sup>-1</sup>

)<sup>-1</sup> cm<sup>-1</sup> at 412 nm) for citrate synthase of the tricarboxylic acid cycle (CS). Units of
enzyme activity were expressed as the conversion of µmol substrate/cell/minute. All
substrates were added in saturating concentrations as determined prior to experimental
measurements. Assays were measured using an xMark Microplate Spectrophotometer
(Biorad, Mississauga, ON, CAN). Data were analyzed using the accompanying
Microplate Manager Software and GraphPad Prism 6 (GraphPad Software, La Jolla,
CA, USA). Biochemicals were supplied by Sigma-Aldrich unless otherwise stated.

256 Western Blotting. Standard DC protein assays were performed on each cell culture sample in order to standardize protein content used for western blotting. RIPA buffer 257 was made by adding one tablet of protease inhibitor (Roche) and one tablet of 258 phosphatase inhibitor (Roche) to 10 mL of the stock solution, which was kept on ice. 259 Once defrosted, the samples were centrifuged at 10,000 rpm for 3 minutes at 4° C. 260 261 Supernatant was removed and the pellets were mechanically homogenized in 20 µL of RIPA buffer with a Teflon pestle for several minutes. The homogenate was chilled on 262 ice for 15 minutes, prior to centrifugation at 10,000 rpm for 10 minutes at 4° C. The 263 264 supernatant was removed and transferred to a new tube and stored on ice until use in the DC protein assay. As previously reported (Wallingford et al., 2017), we prepared a 265 266 standard curve consisting of serial dilutions of bovine serum albumin (BSA; Sigma-267 Aldrich, cat. no. A-7906) and prepared the standards and samples per manufacturer's 268 instructions (Bio-Rad, Hercules, CA, USA). Plates were gently shaken for 15 minutes 269 prior to spectrophotometer readings (xMark Microplate Absorbance Spectrophotometer,

Bio-Rad) taken at 750 nm. Samples were flash frozen in liquid nitrogen and stored at 80° C until further use.

After the amount of protein in each sample was determined, 30 µg of protein from each sample was combined with sample buffer: 2x Laemmli Buffer (Bio-Rad) and 5% 2-Mercaptoethanol (Sigma-Aldrich). Samples were heated for 5 minutes at 95°C, centrifuged briefly, and loaded onto a gradient 4-15% precast polyacrylamide stain-free gel (Bio-Rad).

All experimental samples were aliguoted and prepared for Western blotting with 277 278 the addition of 2x Laemmli Buffer (Bio-Rad) and 5% 2-Mercaptoethanol (Sigma-Aldrich). Samples were heated for 5 minutes at 95°C, centrifuged briefly, and 30 µg of protein 279 from each sample were loaded onto a gradient 4-15% precast polyacrylamide stain-free 280 gel (Bio-Rad). Electrophoretic separation of proteins was done at 125V for 1 hour in a 281 solution of 1X Tris-Glycine SDS running buffer (Bio-Rad). After electrophoresis, the gels 282 were activated with UV light (302 nm) for 1 minute and then transferred onto polyvinyl 283 difluoride membranes (Bio-Rad) using the Trans-Blot Turbo Transfer System (Bio-Rad). 284 The membranes were placed in a 1X tris buffered saline and Tween-20 solution (TBS-285 286 T) and then imaged for total protein using a ChemiDoc Imaging System (Bio-Rad). Membranes were then incubated in a 5% non-fat milk solution in TBS-T for 1 hour at 287 288 room temperature. Following this, membranes were rinsed with TBS-T and then 289 incubated overnight at 4°C with TBS-T containing one of the following primary antibodies: anti-superoxide dismutase 1 (anti-SOD-1; rabbit; 1:5000; Abcam; ab13498), 290 291 anti-SOD2/MnSOD (rabbit; 1:5000; Abcam; ab13533), anti-glutathione peroxidase 1 292 (anti-GPx; rabbit; 1:1000; Abcam; ab22604), anti-glutathione reductase (anti-GR; rabbit;

1:2000; Abcam; ab16801), anti-catalase (anti-CAT; rabbit; 1:2000; Abcam; ab16731), 293 anti-nicotinamide adenine dinucleotide phosphate hydrogen (anti-NADPH) oxidase 2 294 (NOX2; rabbit; 1:5000; Abcam; ab129068), and anti-NADPH oxidase 4 (NOX4; rabbit; 295 1:500; Novus Biologicals; NB110-58851SS). Membranes were washed for 3 x10 296 minutes in TBS-T at room temperature, then incubated for 1 hour in horseradish 297 298 peroxidase conjugated antibody (anti-rabbit, 1:2500, catalogue #: NA934-1ML; GE Healthcare Life Sciences, Mississauga, ON, CA). Membranes were washed for 3 x 10 299 minutes in TBS-T, then developed in the dark for 5 minutes using enhanced 300 301 chemiluminesence developer (Bio-Rad) and imaged. Analysis of relative densitometry was done using Image Lab Software 5.2 (Bio-Rad) and bands of interest were 302 normalized to total protein as well as a positive cross gel control. Normalized 303 densitometry values were expressed relative to WT values. 304 305

306Statistical Analyses. Statistical analyses were conducted using Prism (version 6,307GraphPad Software, RRID: SCR\_002798). Each N represented the number of308independent culture preparations. For comparisons of two groups alone, two-tailed309unpaired t tests were performed. For multiple comparisons the groups were compared310using Two-way ANOVA and Tukey's multiple comparisons were used to determine311effects of genotype or respiration state for each parameter. Data were presented as312mean  $\pm$  SEM. P < 0.05 was considered to be statistically significant.

313

## 314 **Results**

#### 315 Elevated ROS emission in Fmr1-KO cortical astrocytes

High resolution respirometry of permeabilized cortical primary astrocytes was 316 used to determine respiratory capacities across multiple mitochondrial electron transport 317 complexes during both oxidative phosphorylation (OXPHOS) and leak state respiration. 318 Respiration capacity of permeabilized cortical primary astrocytes in the *Fmr*1 KO mice 319 (n=12) was similar to that of WT mice (n=12) during OXPHOS (green section, Fig. 1A), 320 321 as the main effect of genotype in two-way ANOVA was not significant (P=0.395) across all OXPHOS respiration states: stimulation via ADP, glutamate, malate ( $P_{GM}$ ), followed 322 by maximal stimulation of Complex I with pyruvate ( $P_{GMP}$ ), and maximal stimulation of 323 324 Complexes I and II with succinate (P<sub>GMPS</sub>) (Fig. 1C). Maximal stimulation of Complex IV using ascorbate and TMPD ( $P_{Tm}$ ) was also similar between genotypes (P=0.136) (Fig. 325 1D). Leak respiration ( $L_N$ ; *red section*, Fig. 1A) fuelled by glutamate and malate, prior to 326 the addition of ADP, to stimulate oxidative phosphorylation was also similar in *Fmr*1 KO 327 cortical astrocytes compared to WT (pairwise comparison, P=0.0402; Fig. 1B), despite 328 329 the appearance of an upward trend. During respiration, ROS emission from permeabilized cortical astrocytes was 330 significantly elevated in *Fmr*1 KO (n=9) mice compared to WT (n=11) mice (Fig. 2). 331

ROS emission varied as expected between respiration states, as reflected by the

significant main effect of respiration state in two-way ANOVA (P < 0.0001). There was

also a significant main effect of genotype on ROS emission (*P*=0.023), primarily driven

by higher rates of ROS emission in *Fmr*1 KO (n=9) compared to WT (n=11) in the leak

336 state (L<sub>N</sub>) and during submaximal OXPHOS respiration *via* complex I (P<sub>GM</sub>).

In order to assess possible genotypic differences in cellular mitochondrial content
 or distribution within astrocytes, we utilized both fluorescent microscopy and

mitochondrial enzyme assays to examine this. Notably, there were no observable 339 differences in *Fmr1* KO and WT astrocyte mitochondrial content or distribution 340 visualized with Mitotracker Red CMXRos (representative images shown in Fig. 3A-B). In 341 addition, analysis of citrate synthase (CS) activity, a commonly used and validated 342 biomarker for mitochondrial density (Vigelsø, Andersen, and Dela, 2014), showed *Fmr1* 343 344 KO astrocytes with nearly equivalent activity levels as WT astrocytes (P=0.8923; Fig. 3C). We also found genotypic similarities in the activity of Cytochrome c oxidase 345 (complex IV), a marker of mitochondrial cristae surface density, across Fmr1 KO (5.10 346  $\pm 0.43$  fmol/cell/min; n=9) and WT (4.64  $\pm 0.39$  fmol/cell/min; n=8) astrocytes (P=0.4474; 347 data not shown). 348

349

#### 350 Greater NADPH-Oxidase expression in Fmr1-KO cortical astrocytes

Another common source of ROS production within astrocytes is NADPH oxidase 351 352 (NOX), and we compared the expression of two primary NADPH-oxidase isoforms (NOX2 and 4) in WT and *Fmr1* KO primary cortical astrocytes. We found that the 353 protein abundance of NOX2 was elevated in *Fmr1* KO (n=8) cultured cortical astrocytes 354 355 compared to WT (n=7) astrocytes (130.8 ± 8.47% of WT; P<0.05; Fig. 4A). In contrast, we found that the expression levels for NOX4 were similar in cultured cortical astrocytes 356 across *Fmr1* KO (n=8) and WT (n=8) mice (113.0 ± 32.26% of WT; *P*=0.7938; Fig. 4B). 357 Both isoforms were expressed in cultured cortical astrocytes; however, abundance of 358 full-length NOX2 appeared significantly greater than NOX4 (relative intensity per µg of 359 protein; left panels Figure 4A-B). Overall, we found an elevation of NOX2 in *Fmr1* KO 360 cultured cortical astrocytes along with no differences in expression of NOX4. 361

#### 363 Relatively similar antioxidant levels in Fmr1-KO and WT cortical astrocytes

We investigated the relative abundance of various key antioxidant enzymes in astrocytes. The primary enzymes of the antioxidant system in astrocytes are highlighted in Figure 5A. Protein expression of each enzyme was evaluated in primary cortical astrocytes isolated from either *Fmr1* KO or WT mice (Fig. 5 and 6).

368 Catalase (CAT)

369 CAT, an enzyme responsible for the conversion of hydrogen peroxide to water, 370 reduces oxidative damage caused by ROS in astrocytes (Fig. 5A). Here we found a

moderate, yet significant, elevation of CAT in cultures isolated from *Fmr1* KO (n=7) mice

372 compared to those from WT mice (n=7) (157.1 ± 6.66% of WT; P<0.05; Fig. 5B). CAT

expression in postnatal astrocytes appeared relatively weak in both genotypes in

374 comparison to the levels of other antioxidant enzymes.

375 Superoxide Dismutase 1 and 2 (SOD)

Another important enzyme in the antioxidant system is superoxide dismutase 376 (SOD). There are two different polymorphisms of this enzyme within the cell: the Cu/Zn-377 378 SOD (SOD1) enzyme located within the cytosol, and Mn-SOD (SOD2) enzyme found within the mitochondria (Fig. 6A). The expression level of SOD1 in *Fmr1* KO primary 379 380 cortical astrocytes (n=7) was similar to expression levels in WT astrocytes (n=7) (105.8) 381 ± 14.76% of WT; P=0.8287; Fig. 6A). Similarly, the expression of SOD2 in Fmr1 KO 382 (n=7) cortical astrocytes was also similar to that of WT astrocytes (n=7) (95.4 ± 16.45%) 383 of WT; P=0.8305; Fig. 6B).

384 Glutathione Cycle Enzymes

Within the glutathione cycle, glutathione peroxidase (GPx) works with glutathione 385 reductase (GR) to catalyze hydrogen peroxide to water and drives the detoxification of 386 lipid hydroperoxides (Fig. 5A). We found similar expression levels of GPx in primary 387 cortical astrocytes (*Fmr1* KO, n=8; WT, n=7; *P*=0.7964) between genotypes (Fig. 6C). 388 Similarly, the expression levels of GR in *Fmr1* KO primary cortical astrocytes (n=8) were 389 390 comparable to that of WT astrocytes (n=8) (108.3  $\pm$  23.79% of WT; P=0.8234; Fig. 6D). Notably, all SOD and glutathione antioxidant enzymes that we investigated were highly 391 expressed in both WT and *Fmr1* KO cultured cortical primary astrocytes; however, no 392 genotypic differences were observed. 393

394

### 395 **Discussion**

In this study, we measured the mitochondrial respiration of primary cortical 396 astrocytes isolated from WT and Fmr1 KO mice to assess oxygen flux during leak and 397 398 oxidative phosphorylation (OXPHOS) across mitochondrial electron transport 399 complexes. The OXPHOS capacity of the *Fmr1* KO astrocytes was overwhelmingly similar to that of WT astrocytes across successive stimulation of complexes I, II and IV, 400 as well as leak respiration. Simultaneous readings of ROS emission also showed 401 elevated levels in *Fmr1* KO astrocytes compared to WT astrocytes, particularly during 402 403 leak and submaximal OXPHOS respiration via complex I. Interestingly, there were few genotypic differences in the overall expression of enzyme antioxidants that would offset 404 the increase in mitochondrial ROS emission in *Fmr1* KO astrocytes. There was, 405 406 however, significant increases to the expression of NADPH oxidase 2, NOX2, in Fmr1 KO astrocytes that could further augment ROS levels in these cells. Collectively, our 407

results demonstrate that an imbalance between ROS production and elimination
 potentiates oxidative stress in *Fmr1* KO cortical astrocytes and that aberrant astrocyte
 activity contributes to redox imbalance within the FXS brain.

Oxidative stress pathology has been associated with a growing number of 411 neurodevelopmental and neurodegenerative diseases. It is perhaps not surprising that 412 413 enhanced levels of free radicals, as well as increased hydrogen peroxide production and lipid peroxidation activity were identified in brain homogenates of young adult Fmr1 414 KO mice (el Bekay, et al., 2007; de Diego-Otero et al., 2009). In conjunction with this, 415 systemic treatment of these mice with an antioxidant/radical scavenger,  $\alpha$ -Tocopherol, 416 effectively reversed the appearance of oxidative stress markers in a dose-dependent 417 418 manner (de Diego-Otero et al., 2009). During development, synaptic transmission and dendritic spine development are highly dependent on mitochondrial morphology and 419 bioenergetics (Flippo and Strack, 2017). In FXS, both synaptic function and dendritic 420 spine maturation are impaired, an effect partially attributed to reductions of 421 mitochondrial membrane potential and fusion dynamics in *Fmr1* KO neurons (Shen et 422 423 al., 2019). Indeed, ROS overproduction in *Drosophila* leads to mitochondrial dysfunction and overall synaptic reduction within the CNS (Beckhauser, Francis-Oliveira, & De 424 Pasquale et al., 2016), both of which have been noted in the FXS animal model. 425 426 Interestingly, dendritic morphology of *Fmr1* KO neurons is largely normalized by the presence of WT astrocytes and induced in WT neurons by *Fmr1* KO astrocytes, 427 suggesting a prominent role for astrocytes in FXS (Jacobs and Doering, 2010). Given 428 the responsibility of astrocytes in protecting the neuronal microenvironments from 429

430 oxidative stress within the brain, exploration of astrocyte redox regulation in FXS431 warranted further investigation.

Astrocytes have a broad antioxidant response that clears free radicals produced 432 within the CNS; however, they are also a source of ROS and when emission exceeds 433 the detoxifying capacity, oxidative damage can ensue (Chen et al., 2020). Elevated 434 435 levels of ROS are associated with reactive astrogliosis, a process of morphological and functional change that astrocytes undergo in response to CNS stress or damage. 436 Astrocytes within this reactive state for prolonged periods are known to sustain high 437 levels of ROS production, secrete proinflammatory molecules and promote neurotoxicity 438 (reviewed in Rizor et al., 2019). Markers used to characterize reactive astrogliosis, such 439 as glial fibrillary associated protein and pro-inflammatory tumor necrosis factor 2, are 440 both elevated across several regions of the *Fmr1* KO brain (Yuskaitis, Beurel and Jope, 441 2010; Pacey et al., 2015). In addition, *Fmr1* KO astrocytes grown in isolation express 442 enhanced levels of inflammatory induction factors, namely tenascin C and interleukin-6 443 (Krasovska and Doering, 2018). The significant elevations of ROS emission in *Fmr1* KO 444 cortical astrocytes observed here suggest that astrocytes within the FXS brain have a 445 446 higher degree of reactivity and contribute to the oxidative pathogenesis of this disease. During normal conditions, the source of free radicals within astrocytes is primarily 447 448 due to the mitochondria and the NOX pathway. The mitochondria are the greatest 449 source of ROS in astrocytes and ROS production is largely dependent on the function of

the mitochondrial respiratory chain (MRC), particularly complex I during OXPHOS

451 (Zhao, Jiang, Zhang, and Yu, 2019). Interestingly, the MRC of astrocytes is markedly

different than neurons, which depend on OXPHOS for ATP production. In neurons,

complex I is predominantly assembled into supercomplexes that support higher 453 mitochondrial respiration with low ROS production (Bianchi et al., 2004). In contrast, the 454 abundance of free, non-bound complex I is higher in astrocytes, and directly correlates 455 with higher ROS production by comparison (Lopez-Fabuel et al., 2016). Whether MRC 456 organization is altered in FXS is unknown, but inefficient MRC complex activity and 457 458 compromised ATP production in the cerebral cortex of *Fmr1* KO mice has been reported (D'Antoni et al., 2019). Notably, the difference of ROS emission rate in the 459 *Fmr1* KO astrocytes was not likely due to differences in mitochondrial volume or cristae 460 surface density given the similarities in citrate synthase and cytochrome c oxidase 461 activities between *Fmr1* KO and WT astrocytes, nor to changes in mitochondrial 462 organization since distribution was comparable between genotypes. 463

The NADPH-oxidase pathway is another important source of ROS production 464 within astrocytes. This family of enzymes contains 7 members, with NOX2 and 4 being 465 the most abundant in the CNS (Sorce et al., 2017). Within the cell, NOX enzymes are 466 located in the plasma membrane, as well as membranes of cellular organelles, including 467 the endoplasmic reticulum and endosomes. Both NOX2 and 4 are expressed by 468 469 astrocytes to varying degrees at rest but increase in expression and activity in response to stress. For instance, NOX2 levels are elevated during astrogliosis and is significantly 470 upregulated by increasing levels of amyloid- $\beta$  observed in Alzheimer's disease (Chay et 471 al., 2017). Other stresses, such as lipopolysaccharide exposure or hypo-osmotic 472 swelling, also lead to substantial increases of ROS production via NOX activation in 473 astrocytes (Reinehr et al., 2007). Previous studies have reported greater generalized 474 NADPH-oxidase activity within *Fmr1* KO brain tissue (el Bekay, et al., 2007), and our 475

results suggest that this arises at least partly from greater expression of NOX2 in 476 astrocytes. The lack of differences between NOX4 in *Fmr1* KO and WT astrocytes 477 suggests that NOX2 may be solely responsible for any differences in FXS. 478 In the healthy CNS, astrocytes also employ several mechanisms of 479 neuroprotection during excitatory transmission. Glutamate is the primary excitatory 480 481 neurotransmitter within the CNS, but if high amounts remain within the synaptic cleft, overactivation of ionotropic glutamate receptors leads to calcium overload, generation of 482 ROS and neurotoxicity (Reynolds and Hastings, 1995). As a defence, astrocytes 483 actively transport glutamate out of the cleft via the glutamate transporters GLAST, GLT-484 1 and EAAC1. Expression of GLT-1 in particular is significantly reduced in FMRP 485 deficient astrocytes, which leads to impaired glutamate uptake and enhanced neuronal 486 excitability within the somatosensory cortex (Higashimori et al., 2013; 2016). Astrocytes 487 also protect neurons via a robust antioxidant system that uses several different 488 489 enzymes to neutralize hydrogen peroxide within the synaptic zone. Given the reduction of GLT-1 and the increase in ROS, we anticipated the antioxidant system to be 490 enhanced in *Fmr1* KO astrocytes. 491

Astrocytes are the primary source of glutathione, which acts in conjunction with glutathione peroxidase (GPx) to catalyse the reduction of hydrogen peroxide and peroxide radicals (Harvey et al., 2009). A previous report found that expression and activity of glutathione peroxidase was significantly reduced in 4-month-old *Fmr*1 KO mice brains (El Bekay et al. 2007). In contrast, we found that the expression of GPx or glutathione reductase (GR), the enzyme that reduces glutathione disulfide to glutathione, were not altered in *Fmr*1 KO astrocytes in comparison to WT. It may be that

dysregulation of GPx only occurs at later time points in development since differences
between *Fmr1* KO and WT brain tissue have not been found in early postnatal stages
(el Bekay et al., 2007).

Other key antioxidant enzymes regulated by ROS levels are catalase and 502 superoxide dismutase (SOD). Interestingly, we did find that the expression of catalase 503 504 was significantly elevated in *Fmr1* KO astrocytes in comparison to WT cells. Catalase, an enzyme responsible for the reduction of hydrogen peroxide, is found in relatively low 505 abundance within the cytoplasm and peroxisomes in the mammalian brain (Mavelli et 506 507 al., 1982). Given the low expression of catalase at that age, the increase of catalase expression observed within Fmr1 KO astrocytes did not appear to be sufficient to 508 effectively overcome ROS production observed here. The superoxide dismutase (SOD) 509 polymorphisms, Cu-Zn and Mn-SOD (SOD1 and SOD2, respectively) work upstream to 510 many of the other antioxidant enzymes to neutralize superoxides into hydrogen 511 512 peroxide and  $O_2^-$ , which are then reduced by catalase and others. Both forms are expressed widely within the CNS, SOD1 being within the cytosol and SOD2 in the 513 mitochondria. FMRP is known to regulate the translation of SOD1 protein within the 514 515 brain, and expression of SOD1 was reported to be reduced in several brain regions of postnatal Fmr1 KO mice compared to WT (Bechara et al., 2009). Since FMRP 516 517 expression is normally quite high within the early postnatal brain, we were surprised by 518 the similarities of SOD1 and 2 within the WT and *Fmr*1 KO astrocytes. This suggests 519 that while FMRP may be an important regulator of SOD1, other regulatory factors 520 appear to compensate for the loss of FMRP expression in *Fmr1* KO astrocytes. 521

# 522 **Conclusions**

While the study of possible mitochondrial or OXPHOS perturbations in isolated 523 524 astrocytes is advantageous to understand changes due to the genetic variation in this cell type, future studies examining these relationships in vivo will help determine the 525 degree to which it contributes to oxidative stress in FXS. For instance, the metabolic 526 demand on astrocytes is greatly enhanced during neuronal activity and the fact that 527 mitochondrial respiration is significantly higher in permeabilized tissue compared to cell 528 preparations (Schopf et al., 2016; Van Bergen et al., 2014), it is likely that basal 529 mitochondrial respiration and ROS emission is largely underestimated in our study. 530 This, and the abnormal level of activation noted in  $Fmr1^{-/-}$  cortical neurons (Bülow et al., 531 532 2019), may underscore some of the key differences that we found in our primary cells compared to studies examining cortical tissue of these mice. 533 Overall, our observations compliment previous studies in this area and point to a 534

pivotal role of oxidative imbalance in the pathology of FXS. We show that changes to
astrocyte-mediated ROS emission may in fact contribute to the loss of oxidative
homeostasis within the FXS cortex, rather than prevent it via the antioxidant system.
This study not only identifies novel pathophysiology associated with glial cell biology in
FXS, but also highlights the need for innovative therapeutic strategies that target factors
triggering oxidative stress in FXS and related neurological disorders.

541

# 542 **References**

- Bains, J. S., & Shaw, C. A. (1997). Neurodegenerative disorders in humans: the role of
  glutathione in oxidative stress-mediated neuronal death. *Brain research reviews,*25(3), 335-58.
- 546 Bechara, E. G., Didiot, M. C., Melko, M., Davidovic, L., Bensaid, M., Martin, P., ...
- 547 Bardoni, B. (2009). A Novel Function for Fragile X Mental Retardation Protein in 548 Translational Activation. *PLoS Biology*, *7*(1), e1000016.
- 549 Beckhauser, T. F., Francis-Oliveira, J., & De Pasquale, R. (2016). Reactive Oxygen
- 550 Species: Physiological and Physiopathological Effects on Synaptic Plasticity.
- 551 *Journal of Experimental Neuroscience, 10*(Suppl 1), 23-48.
- Bianchi, K., Rimessi, A., Prandini, A., Szabadkai, G., & Rizzuto, R. (2004). Calcium and
  mitochondria: mechanisms and functions of a troubled relationship. *Biochimica et biophysica atca, 1742*(1-3), 119-31.
- Blanc, E. M., Keller, J. N., Fernandez, S., & Mattson, M. P. (1998). 4-hydroxynonenal, a
  lipid peroxidation product, impairs glutamate transport in cortical astrocytes. *Glia*,
  22(2), 149-60.
- Brookes, P. S. (2005). Mitochondrial H+ leak and ROS generation: An odd couple. *Free Radical Biology and Medicine*, 38(1), 12-23.
- 560 Bülow, P., Murphy, T. J., Bassell, G. J., & Wenner, P. (2019). Homeostatic Intrinsic
- 561 Plasticity Is Functionally Altered in Fmr1 KO Cortical Neurons. *Cell Reports*, 26(6),
- 562 1378-1388.e3. https://doi.org/https://doi.org/10.1016/j.celrep.2019.01.035

563	Chay, K., Koong, K., Hwang, S., Kim, J., & Bae, C. (2017). NADPH Oxidase Mediates
564	β-Amyloid Peptide-Induced Neuronal Death in Mouse Cortical Cultures.
565	Chonnam medical journal, 53(3), 196-202.
566	Chen, Q., Huang, J., Tang, X., Liu, C., Huang, K., et al. (2020) The role of astrocytes in
567	oxidative stress of central nervous system: A mixed blessing. Cell Proliferation,
568	53(3), e12781.
569	Cobley, J. N., Fiorello, M. L., & Bailey, D. M. (2018). 13 reasons why the brain is
570	susceptible to oxidative stress. <i>Redox Biology, 15</i> , 490-503.
571	Coyle, J. T., & Puttfarcken, P. (1993). Oxidative Stress, Glutamate, and
572	Neurodegenerative Disorders. Science, 262, 689-695.
573	Cuadrado, A., Gimenez-Liorente, D., Kojic, A., Gomez-Lopez, G., Marti-Renom, M., &
574	Losada, A. (2019). Specific Contributions of Cohesin-SA1 and CohesinSA2 to
575	TADs and Polycomb Domains in Embryonic. Cell Press, 27, 3500-3510.
576	D'Ambrosia, M., Guerriero, A., Debitus, C., Ribes, O., Pusset, J., Leroy, S., & Pietra, F.
577	(1993). Agelastatin A, a new skeleton cytotoxic alkaloid of the oroidin family.
578	Isolation from the axinellid sponge Agelas dendromorpha of the coral sea.
579	Journal of Chemical Society(16), 1305-1306.
580	D'Antoni, S., De Bari, L., Valenti, D., Borro, M., Bonaccorso, C. M., Simmaco, M.,
581	Catania, M. V. (2019, January 1). Aberrant mitochondrial bioenergetics in the
582	cerebral cortex of the Fmr1 knockout mouse model of fragile X syndrome.
583	Journal of Biological Chemistry. doi:https://doi.org/10.1515/hsz-2019-0221
584	de Diego-Otero, Y., Romero-Zerbo, Y., el Bekay, R., Decara, J., Sanchez, L.,
585	Rodriguez-de Fonseca, & del Arco-Herrera, I. (2009). a-Tocopherol Protects

586	Against Oxidative Stress in the Fragile X Knockout Mouse: an Experimental
587	Therapeutic Approach for the Fmr1 Deficiency. Neuropyschopharmacology, 34,
588	1011-1026.

Dringen, R., Pfeiffer, B., & Hamprecht, B. (1999). Synthesis of the Antioxidant
 Glutathione in Neurons: Supply by Astrocytes of CysGly as Precursor for
 Neuronal Glutathione. *Journal of neuroscience*, *19*(2), 562-569.

el Bekay, R., Romero-Zerbo, Y., Decara, J., Sanchez-Salido, L., Del Arco-Herrar, I.,

593 Rodriguez-de Fonseca, F., & de Diego-Otero, Y. (2007). Enhanced markers of

594 oxidative stress, altered antioxidants and NADPH-oxidase activation in brains

595 from Fragile X mental retardation 1-deficient mice, a pathological model for

596 Fragile X syndrome. *Europena Journal of Neuroscience*, 26, 3169-3180.

597 Flippo, K. H., & Strack, S. (2017). Mitochondrial dynamics in neuronal injury,

598 development and plasticity. *Journal of cell science*, *130*(4), 671-681.

599 Gnaiger. (2014). *Mitochondrial pathways and respiratory control. An introduction to* 

600 OXPHOS analysis. 4th ed. Innsbruck: Oroboros MiPNet Publications.

601 Gray, S., & Jandeleit-Dahm, K. (2015). The role of NADPH oxidase in vascular

disease–hypertension, atherosclerosis & stroke. *Current pharmaceutical design*,
21, 5933-5944.

Griffiths, K. K., Wang, A., Wang, L., Tracey, M., Kleiner, G., Quinzii, C. M., . . . Levy, R.

J. (under review). Inefficient Thermogenic Mitochondrial Respiration Due to Futile
 Proton Leak in a Mouse Model of Fragile X Syndrome. *Cell Press*.

Harvey, C., Thimmulappa, R., Singh, A., Blake, D., Ling, G., Wakabayashi, N., . . .

Biswal, S. (2009). Nrf2-regulated glutathione recycling independent of

- biosynthesis is critical for cell survival during oxidative stress. *Free radical biology & medicine, 46*(4), 443-53.
- Herrera, F., Sainz, R. M., Mayo, J. C., Martin, V., Antolin, I., & Rodriguez, C. (2008).
- Glutamate induces oxidative stress not mediated by glutamate receptors or
- 613 cystine transporters: protective effect of melatonin and other antioxidants.
- 614 Journal of Pineal Research.
- Higashimori, H., Schin, C. S., Chiang, M. S., Morel, L., Shoneye, T. A., Nelson, D. L., &
- Yang, Y. (2016). Selective Deletion of Astroglial FMRP Dysregulates Glutamate
- Transporter GLT1 and Contributes to Fragile X Syndrome Phenotypes In Vivo.
- 618 *Journal of Neuroscience, 36*(27), 7079-94.
- Jacobs, S. & Doering, L. (2010) Astrocytes prevent abnormal neuronal development in
   the fragile X mouse. *Journal of Neuroscience*, *30 (12)*, 4508-14.
- Jain, A., Martensson, J., Stole, E., Auld, P. A., & Meister, A. (1991). Glutathione
- deficiency leads to mitochondrial damage in brain. *Proceedings of the National*
- Academy of Sciences of the United States of America, 88(5), 1913-1917.
- Jou, M.-J. (2008). Pathophysiological and pharmacological implications of mitochondria-
- 625 targeted reactive oxygen species generation in astrocytes. *Advanced drug*
- 626 *delivery reviews, 60*(13-14), 1512-26.
- Khayachi, A., Gwizdek, C., Poupon, G., Alcor, D., Chafi, M., Casse, F., . . . Martin, R.
- 628 (2018). Sumoylation regulates FMRP-mediated dendritic spine elimination and
- maturation. *Nature communications*, *9*(1), 757.

630	Korge, P., Honda, H. M., & Weiss, J. N. (2003). Effects of fatty acids in isolated
631	mitochondria: implications for ischemic injury and cardioprotection. American
632	Journal of Physiology. Heart and Circulatory Physiology, 285(1), H259-69.
633	Krasovska, V., & Doering, L. (2018). Regulation of IL-6 Secretion by Astrocytes via
634	TLR4 in the Fragile X Mouse Model. Frontiers in molecular neuroscience, 11,
635	272.
636	Kunze, A., Lengacher, S., Dirren, E., Aebischer, P., Magistretti, P. J., & Renaud, P.
637	(2013). Astrocyte-neuron co-culture on microchips based on the model of SOD
638	mutation to mimic ALS. Integrative biology, 5, 964-975.
639	Liemburg-Apers, D. C., Willems, P., Koopman, W., & Grefte, S. (2015). Interactions
640	between mitochondrial reactive oxygen species and cellular glucose metabolism.
641	Archives of Toxicology, 89, 1209-1226.
642	Lopez-Fabuel, I., Le Douce, J., Logan, A., James, A. M., Bonvento, G., Murphy, M.,
643	Bolanos, J. (2016). Complex I assembly into supercomplexes determines
644	differential mitochondrial ROS production in neurons and astrocytes.
645	Proceedings of the National Academy of Sciences of the United States of
646	<i>America, 113</i> (46), 13063-13068.
647	Mahmoud, S., Gharagozloo, M., Simard, C., & Gris, D. (2019). Astrocytes Maintain
648	Glutamate Homeostasis in the CNS by Controlling the Balance between
649	Glutamate Uptake and Release. <i>Cells, 8</i> (2), 184.
650	Mavelli, I., Ciriolo, M., & Rotilio, G. (1982). Superoxide dismutase, glutathione

651 peroxidase and catalase in oxidative hemolysis. A Study of Fanconi's anemia

- erythrocytes. *Biochemical and Biophysical Research Communications*, 106(2),
  286-90.
- McBean, G. J. (2018). Astrocyte Antioxidant Systems. *Antioxidants, 7*(112).
- Pacey, L., Guan, S., Tharmalingam, S., Thomsen, C., & Hampson, D. (2015). Persistent
   astrocyte activation in the fragile X mouse cerebellum. *Brain and behaviour,*
- 657 *5*(10), e00400.
- Pangrazzi, L., Balasco, L., & Bozzi, Y. (2020). Oxidative Stress and Immune System
   Dysfunction in Autism Spectrum Disorders. *International journal of molecular sciences*, *21*(9), 3293.
- Penagarikano, O., Mulle, J. G., & Warren, S. T. (2007). The Pathophysiology of Fragile
   X Syndrome. *The Annual Review of Genomics and Human Genetics*, *8*, 109-29.
- Raspa, M., Wheeler, A. C., & Riley, C. (2017, June). Public Health Literature Review of
  Fragile X Syndrome. *Pediatrics*, *139*(3), e20161159.
- Reinehr, R., Gorg, B., Becker, S., Qvartskhava, N., Bidmon, H., Selbach, O., ...
- Haussinger, D. (2007). Hypoosmotic swelling and ammonia increase oxidative
- stress by NADPH oxidase in cultured astrocytes and vital brain slices. *Glia*, *55*,
  758-771.
- 669 Reynolds, I., & Hastings, T. (1995). Glutamate induces the production of reactive
- oxygen species in cultured forebrain neurons following NMDA receptor
  activation. *Journal of neuroscience*, *15*(5 Pt 1), 3318-27.
- Rizor, A., Pajarillo, E., Johnson, J., Aschner, M., & Lee, E. (2019). Astrocytic
- 673 Oxidative/Nitrosative Stress Contributes to Parkinson's Disease Pathogenesis:
- The Dual Role of Reactive Astrocytes. *Antioxidants, 8*(8), 265.

675	Ross, M. A. (2000). Could oxidative stress be a factor in neurodevelopmental
676	disorders? Prostalglandins, Leukotrienes and Essential Fatty Acids, 63, 61-63.
677	Ross-Inta, C., Omanska-Klusek, A., Wong, S., Barrow, C., Garcia-Arocena, D.,
678	Iwahashi, C., Giulivi, C. (2010). Evidence of mitochondrial dysfunction in
679	fragile X-associated tremor/ataxia syndrome. Biochemical Journal, 429(3), 545-
680	552.
681	Salim, S. (2017). Oxidative Stress and the Central Nervous System. The Journal of
682	Pharmacology and Experimental Therapeutics, 360, 201-205.
683	Schöpf, B., Schäfer, G., Weber, A., Talasz, H., Eder, I. E., Klocker, H., & Gnaiger, E.
684	(2016). Oxidative phosphorylation and mitochondrial function differ between human
685	prostate tissue and cultured cells. <i>The FEBS Journal</i> , 283(11), 2181–2196.
686	https://doi.org/10.1111/febs.13733
687	Shanmugasundaram, K., Nayak, B., Friedrichs, W., Kaushik, D., Rodriguez, R., & Block,
688	K. (2017). NOX4 functions as a mitochondrial energetic sensor coupling cancer
689	metabolic reprogramming to drug resistance. Nature communications, 997.
690	Shen, M., Wang, F., Li, M., Sah, N., Stockton, M. E., Tidei, J. J., Zhao, X. (2019).
691	Reduced mitochondrial fusion and Huntingtin levels contribute to impaired
692	dendritic maturation and behavioral deficits in Fmr1 mutant mice. 22(3), 386-400.
693	Sorce, S., Stocker, R., Seredenina, T., Holmdahl, R., Aguzzi, A., Chio, A., Jaquet, V.
694	(2017). NADPH oxidases as drug targets and biomarkers in neurodegenerative
695	diseases: What is the evidence? Free radical biology & medicine, 112, 387-396.

696	Stephen, TL., Gupta-Agarwal, S., & Kittler, J. T. (2014). Mitochondrial Dynamics in
697	astrocytes. Biochemical Society Transactions, 42(5).
698	Turrens, J. F. (2003). Mitochondrial formation of reactive oxygen species. Journal of
699	Physiology, 335-344.
700	Vallet, P., Charnay, Y., Steger, K., Ogier-Denis, E., Kovari, E., Herrmann, F.,
701	Szanto, I. (2005). Neuronal expression of the NADPH oxidase NOX4, and its
702	regulation in mouse experimental brain ischemia. Journal of Neuroscience,
703	<i>132</i> (2), 233-238.
704	Van Bergen, N., Blake, R., Crowston, J., & Trounce, I. (2014). Oxidative
705	phosphorylation measurement in cell lines and tissues. <i>Mitochondrion</i> , 15.
706	https://doi.org/10.1016/j.mito.2014.03.003
707	Wallingford, J., Scott, A. L., Rodrigues, K., & Doering, L. C. (2017). Altered
708	Developmental Expression of the Astrocyte-Secreted Factors Hevin and
709	SPARC in the Fragile X Mouse Model. Frontiers in Molecular Neuroscience, 10,
710	268. https://doi.org/10.3389/fnmol.2017.00268
711	Wang, S., Lim, S., Wang, Y., Lin, H., Lai, M., Ko, C., & Wang, J. (2018). Astrocytic
712	CCAAT/Enhancer-binding protein delta contributes to reactive oxygen species
713	formation in neuroinflammation. <i>Redox biology, 16</i> , 104-112.
714	Wang, Y., Branicky, R., Noe, A., & Hekimi, S. (2018). Superoxide dismutases: Dual
715	roles in controlling ROS damage and regulating ROS signaling. Journal of cell
716	<i>biology, 217</i> (6), 1915-1928.

- Wilson, J. X. (1997). Antioxidant defense of the brain: a role for astrocytes. *Canadian Journal of Physiology and Pharmacology*, *75*, 1149-1163.
- Yuskaitis, C. J., Beurel, E., & Jope, R. S. (2010). Evidence of reactive astrocytes but not
- peripheral immune system activation in a mouse model of Fragile X syndrome.
- 721 *Biochimica et biophysica acta, 1802*(11), 1006-12.
- Zhao, R., Jiang, S., Zhang, L., & Yu, Z. (2019). Mitochondrial electron transport chain,
- ROS generation and uncoupling (Review). *International journal of molecular*
- *medicine*, *44*(1), 3-15.
- 725
- 726
- 727



**Figure 1.** (*A*) Typical high resolution respirometry trace of WT oxygen consumption in permeabilized cultured astrocytes. Respiration rates of WT (n=13), and *Fmr*1 KO (n=14) permeabilized primary cortical astrocytes were stimulated via sequential application of exogenous substrates: addition of glutamate and malate for leak respiration ( $L_N$ ); then ADP ( $P_{GM}$ ) for oxidative phosphorylation via complex I; pyruvate ( $P_{GMP}$ ) for maximal stimulation of complex I; succinate ( $P_{GMPS}$ ) for stimulation of complex I; and finally, ascorbate and TMPD ( $P_{Tm}$ ) for stimulation of complex IV. No differences in leak or oxidative phosphorylation capacity was measured between WT (white) and Fmr1 KO astrocytes (black; *B-D*). Error bars, SEM.



**Figure 2.** (*A*) Typical high resolution respirometry trace of WT  $H_2O_2$  emissions in permeabilized cultured astrocytes. (*B*)  $H_2O_2$  emission rates of WT (n=9) permeabilized primary cortical astrocytes were significantly lower than that of *Fmr*1 KO astrocytes (n=11). Respiration states were stimulated as previously stated: leak respiration (L<sub>N</sub>) via glutamate and malate; oxidative phosphorylation of complex I with glutamate, malate, and ADP (P<sub>GM</sub>); maximal stimulation of complex I with glutamate, malate, ADP, and pyruvate (P<sub>GMP</sub>); and stimulation of complex II with glutamate, malate, ADP, pyruvate, and succinate (P<sub>GMPS</sub>) \*- Significant effect (P<0.05). Error bars, SEM.



**Figure 3.** Representative images of WT (*A*) and *Fmr*1 KO (*B*) cortical cultured astrocytes stained with Mitotracker Red CMXRos. Scale bar, 20µm. (*C*) Activity of citrate synthase in WT (n=8) and Fmr1 KO (n=9) primary astrocytes. Astrocytes showed no significant genotypic difference in citrate synthase activity. Error bars, SEM.



**Figure 4.** Protein expression of NADPH-oxidase (NOX) 2 and 4 in primary cortical astrocytes (n=7-8/group) isolated from *Fmr*1 KO mice. (A) NOX2 expression was elevated in Fmr1 KO (black) astrocytes compared to WT astrocytes (white). (B) There were no genotypic differences between WT and *Fmr*1 KO NOX4 expression. \*- Significant effect (P<0.05). Error bars, SEM.



**Figure 5.** (*A*) Schematic of reactive oxygen species production and key antioxidant processes present in astrocytes to prevent oxidative damage. Protein expression of catalase in primary astrocytes (*B*; n=7/group) was elevated in *Fmr*1 KO (black) mice compared to WT (white). \*- Significant effect (P<0.05). Error bars, SEM.



**Figure 6.** Protein expression of superoxide dismutase (SOD), glutathione peroxidase (GPx) and glutathione reductase (GR) antioxidant enzymes in WT and Fmr1 KO cultured primary astrocytes (n=7-8/group). No differences of SOD1 (A), SOD2 (B), GPx (C), or GR (D) were observed between WT (white) and *Fmr*1 KO (black) primary astrocytes. Error bars, SEM.